ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $4.11 billion. The enterprise value is $4.14 billion.
| Market Cap | 4.11B |
| Enterprise Value | 4.14B |
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 236.39 million shares outstanding. The number of shares has increased by 8.99% in one year.
| Current Share Class | 236.39M |
| Shares Outstanding | 236.39M |
| Shares Change (YoY) | +8.99% |
| Shares Change (QoQ) | +1.09% |
| Owned by Insiders (%) | 1.79% |
| Owned by Institutions (%) | 89.97% |
| Float | 232.07M |
Valuation Ratios
The trailing PE ratio is 62.07 and the forward PE ratio is 25.65. ADMA Biologics's PEG ratio is 1.28.
| PE Ratio | 62.07 |
| Forward PE | 25.65 |
| PS Ratio | 10.48 |
| Forward PS | 8.60 |
| PB Ratio | 17.74 |
| P/TBV Ratio | 18.05 |
| P/FCF Ratio | 51.81 |
| P/OCF Ratio | 47.80 |
| PEG Ratio | 1.28 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.87, with an EV/FCF ratio of 52.12.
| EV / Earnings | 60.73 |
| EV / Sales | 10.81 |
| EV / EBITDA | 32.87 |
| EV / EBIT | 35.16 |
| EV / FCF | 52.12 |
Financial Position
The company has a current ratio of 7.09, with a Debt / Equity ratio of 0.48.
| Current Ratio | 7.09 |
| Quick Ratio | 3.05 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 0.87 |
| Debt / FCF | 1.40 |
| Interest Coverage | 6.82 |
Financial Efficiency
Return on equity (ROE) is 35.55% and return on invested capital (ROIC) is 22.71%.
| Return on Equity (ROE) | 35.55% |
| Return on Assets (ROA) | 19.89% |
| Return on Capital (ROIC) | 22.71% |
| Revenue Per Employee | $613,476 |
| Profits Per Employee | $109,186 |
| Employee Count | 624 |
| Asset Turnover | 1.04 |
| Inventory Turnover | 1.15 |
Taxes
In the past 12 months, ADMA Biologics has paid $5.22 million in taxes.
| Income Tax | 5.22M |
| Effective Tax Rate | 7.12% |
Stock Price Statistics
The stock price has increased by +312.32% in the last 52 weeks. The beta is 0.72, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | +312.32% |
| 50-Day Moving Average | 18.83 |
| 200-Day Moving Average | 13.58 |
| Relative Strength Index (RSI) | 36.96 |
| Average Volume (20 Days) | 2,772,633 |
Short Selling Information
The latest short interest is 12.91 million, so 5.46% of the outstanding shares have been sold short.
| Short Interest | 12.91M |
| Short Previous Month | 14.24M |
| Short % of Shares Out | 5.46% |
| Short % of Float | 5.56% |
| Short Ratio (days to cover) | 3.47 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $382.81 million and earned $68.13 million in profits. Earnings per share was $0.28.
| Revenue | 382.81M |
| Gross Profit | 189.41M |
| Operating Income | 117.69M |
| Pretax Income | 39.17M |
| Net Income | 68.13M |
| EBITDA | 125.89M |
| EBIT | 117.69M |
| Earnings Per Share (EPS) | $0.28 |
Balance Sheet
The company has $86.71 million in cash and $111.38 million in debt, giving a net cash position of -$24.68 million or -$0.10 per share.
| Cash & Cash Equivalents | 86.71M |
| Total Debt | 111.38M |
| Net Cash | -24.68M |
| Net Cash Per Share | -$0.10 |
| Equity (Book Value) | 231.89M |
| Book Value Per Share | 0.98 |
| Working Capital | 273.30M |
Cash Flow
In the last 12 months, operating cash flow was $86.05 million and capital expenditures -$6.67 million, giving a free cash flow of $79.39 million.
| Operating Cash Flow | 86.05M |
| Capital Expenditures | -6.67M |
| Free Cash Flow | 79.39M |
| FCF Per Share | $0.34 |
Margins
Gross margin is 49.48%, with operating and profit margins of 30.74% and 17.80%.
| Gross Margin | 49.48% |
| Operating Margin | 30.74% |
| Pretax Margin | 19.16% |
| Profit Margin | 17.80% |
| EBITDA Margin | 32.89% |
| EBIT Margin | 30.74% |
| FCF Margin | 20.74% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.99% |
| Shareholder Yield | -8.99% |
| Earnings Yield | 1.66% |
| FCF Yield | 1.93% |
Analyst Forecast
The average price target for ADMA Biologics is $21.25, which is 22.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.25 |
| Price Target Difference | 22.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 25.99% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 8.57 and a Piotroski F-Score of 8.
| Altman Z-Score | 8.57 |
| Piotroski F-Score | 8 |